Compounds > 4-((2-chloroethyl)(2-mesyloxyethyl)amino)benzoylglutamic acid
Page last updated: 2024-12-07

4-((2-chloroethyl)(2-mesyloxyethyl)amino)benzoylglutamic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

4-((2-chloroethyl)(2-mesyloxyethyl)amino)benzoylglutamic acid: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID129763
CHEMBL ID12842
SCHEMBL ID887827
MeSH IDM0244344

Synonyms (13)

Synonym
cmda
CHEMBL12842
(2s)-2-[[4-[2-chloroethyl(2-methylsulfonyloxyethyl)amino]benzoyl]amino]pentanedioic acid
122665-73-0
n-(4-((2-chloroethyl)(2-((methylsulfonyl)oxy)ethyl)amino)benzoyl)-l-glutamic acid
4-cema-benzoyl-glutamic acid
l-glutamic acid, n-(4-((2-chloroethyl)(2-((methylsulfonyl)oxy)ethyl)amino)benzoyl)-
4-((2-chloroethyl)(2-mesyloxyethyl)amino)benzoylglutamic acid
SCHEMBL887827
DTXSID30153674
(s)-2-(4-((2-chloroethyl)(2-((methylsulfonyl)oxy)ethyl)amino)benzamido)pentanedioic acid
4-[(2-chloroethyl)(2-mesyloxyethyl)amino]benzoyl-l-glutamic acid
(s)-2-(4-((2-chloroethyl)(2-((methylsulfonyl)oxy)ethyl)amino)benzamido)pentanedioicacid

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"Experiencing adverse events (AEs) during mass drug administration (MDA) could affect participation in future MDAs."( Impact of adverse events during community-wide mass drug administration for soil-transmitted helminths on subsequent participation-a Theory of Planned Behaviour analysis.
Ajjampur, SSR; Aruldas, K; Israel, GJ; Johnson, J; Kaliappan, SP; Means, AR; Ramesh, RM; Saxena, M; Titus, A; Walson, JL, 2023)		0.91

Compound-Compound Interactions

ExcerptReferenceRelevance
" The resulting conjugate was used in combination with a prodrug of a benzoic acid mustard alkylating agent to treat human colon tumor xenografts in a two-step targeting strategy, antibody-directed enzyme prodrug therapy (ADEPT)."( Antitumor effects of an antibody-carboxypeptidase G2 conjugate in combination with a benzoic acid mustard prodrug.
Bagshawe, KD; Blakey, DC; Boyle, FT; Burke, PJ; East, S; Melton, RG; Springer, CJ; Valcaccia, BE; Wright, AF, )		0.13
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Carboxypeptidase G2Pseudomonas aeruginosa PAO1Km3.40003.40003.40003.4000AID236273
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (22)

Assay IDTitleYearJournalArticle
AID236273Km against carboxypeptidase G2 in inhibitory kinetic assay2005Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16
Novel fluorinated prodrugs for activation by carboxypeptidase G2 showing good in vivo antitumor activity in gene-directed enzyme prodrug therapy.
AID237174Chemical half life period as substrates of CPG2 was determined2005Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16
Novel fluorinated prodrugs for activation by carboxypeptidase G2 showing good in vivo antitumor activity in gene-directed enzyme prodrug therapy.
AID24282Chemical half-life in percholate at 37 degree was determined1994Journal of medicinal chemistry, Jul-22, Volume: 37, Issue:15
Novel prodrugs of alkylating agents derived from 2-fluoro- and 3-fluorobenzoic acids for antibody-directed enzyme prodrug therapy.
AID25789Kinetics of potential prodrugs as substrates for carboxypeptidase G2 was determined and reported as apparent second order constant1994Journal of medicinal chemistry, Jul-22, Volume: 37, Issue:15
Novel prodrugs of alkylating agents derived from 2-fluoro- and 3-fluorobenzoic acids for antibody-directed enzyme prodrug therapy.
AID25686Half life period was reported1996Journal of medicinal chemistry, Mar-01, Volume: 39, Issue:5
New mustard prodrugs for antibody-directed enzyme prodrug therapy: alternatives to the amide link.
AID248608Cytotoxicity aganist MDA MB361 cell line MDA MB 361 expressing stCPG2(Q)3 done for 1 hr with compound dissolved in DMSO2005Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16
Novel fluorinated prodrugs for activation by carboxypeptidase G2 showing good in vivo antitumor activity in gene-directed enzyme prodrug therapy.
AID48465Michaelis-Menten constant for bacterial Carboxypeptidase1996Journal of medicinal chemistry, Mar-01, Volume: 39, Issue:5
New mustard prodrugs for antibody-directed enzyme prodrug therapy: alternatives to the amide link.
AID102183Inhibitory concentration was evaluated against colorectal tumar cell line LoVo1996Journal of medicinal chemistry, Mar-01, Volume: 39, Issue:5
New mustard prodrugs for antibody-directed enzyme prodrug therapy: alternatives to the amide link.
AID252297Ratio of IC50 of LacZ cell line to stCPG2(Q)3-expressing cell line2005Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16
Novel fluorinated prodrugs for activation by carboxypeptidase G2 showing good in vivo antitumor activity in gene-directed enzyme prodrug therapy.
AID248715Cytotoxicity against MDA MB361 cell line MDA MB 361 expressing beta-galactosidase done for 1 h with compound dissolved in DMSO2005Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16
Novel fluorinated prodrugs for activation by carboxypeptidase G2 showing good in vivo antitumor activity in gene-directed enzyme prodrug therapy.
AID231125Ratio of the half-life period of the prodrug and the drug was determined2003Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9
Self-immolative nitrogen mustards prodrugs cleavable by carboxypeptidase G2 (CPG2) showing large cytotoxicity differentials in GDEPT.
AID216603Compound was tested for cytotoxicity in WiDr cells engineered for stable expression of beta-galactosidase2003Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9
Self-immolative nitrogen mustards prodrugs cleavable by carboxypeptidase G2 (CPG2) showing large cytotoxicity differentials in GDEPT.
AID101130Compound was evaluated for its cytotoxicity with carboxypeptidase G2 in the colorectal cell line LS174T for 1 hour1994Journal of medicinal chemistry, Jul-22, Volume: 37, Issue:15
Novel prodrugs of alkylating agents derived from 2-fluoro- and 3-fluorobenzoic acids for antibody-directed enzyme prodrug therapy.
AID252296Ratio of IC50 of LacZ cell line to CPG2-expressing cell line2005Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16
Novel fluorinated prodrugs for activation by carboxypeptidase G2 showing good in vivo antitumor activity in gene-directed enzyme prodrug therapy.
AID18267Kinetics of potential prodrugs as substrates for carboxypeptidase G2 was determined and reported as Michaelis-Menten constant1994Journal of medicinal chemistry, Jul-22, Volume: 37, Issue:15
Novel prodrugs of alkylating agents derived from 2-fluoro- and 3-fluorobenzoic acids for antibody-directed enzyme prodrug therapy.
AID101132Compound was evaluated for its cytotoxicity without carboxypeptidase G2 in the colorectal cell line LS174T for 1 hour1994Journal of medicinal chemistry, Jul-22, Volume: 37, Issue:15
Novel prodrugs of alkylating agents derived from 2-fluoro- and 3-fluorobenzoic acids for antibody-directed enzyme prodrug therapy.
AID48464Catalytic rate constant for bacterial Carboxypeptidase1996Journal of medicinal chemistry, Mar-01, Volume: 39, Issue:5
New mustard prodrugs for antibody-directed enzyme prodrug therapy: alternatives to the amide link.
AID25784Kinetics of potential prodrugs as substrates for carboxypeptidase G2 was determined and reported as first order constant1994Journal of medicinal chemistry, Jul-22, Volume: 37, Issue:15
Novel prodrugs of alkylating agents derived from 2-fluoro- and 3-fluorobenzoic acids for antibody-directed enzyme prodrug therapy.
AID236899Kcat against carboxypeptidase G2 in inhibitory kinetic assay2005Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16
Novel fluorinated prodrugs for activation by carboxypeptidase G2 showing good in vivo antitumor activity in gene-directed enzyme prodrug therapy.
AID29094Half-life period (prodrug) was determined2003Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9
Self-immolative nitrogen mustards prodrugs cleavable by carboxypeptidase G2 (CPG2) showing large cytotoxicity differentials in GDEPT.
AID216604Compound was tested for cytotoxicity in WiDr cells engineered for stable expression of surface-tethered CPG22003Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9
Self-immolative nitrogen mustards prodrugs cleavable by carboxypeptidase G2 (CPG2) showing large cytotoxicity differentials in GDEPT.
AID248725Cytotoxicity aganist MDA MB361 cell line MDA MB 361 expressing carboxypeptidase G2 done for 1 hr with compound dissolved in DMSO2005Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16
Novel fluorinated prodrugs for activation by carboxypeptidase G2 showing good in vivo antitumor activity in gene-directed enzyme prodrug therapy.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (19)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's7 (36.84)18.2507
2000's7 (36.84)29.6817
2010's0 (0.00)24.3611
2020's5 (26.32)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.93

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.93 (24.57)
Research Supply Index3.30 (2.92)
Research Growth Index4.23 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.93)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials5 (23.81%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other16 (76.19%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
gentamicin
Gentamicins: A complex of closely related aminoglycosides obtained from MICROMONOSPORA purpurea and related species. They are broad-spectrum antibiotics, but may cause ear and kidney damage. They act to inhibit PROTEIN BIOSYNTHESIS.		1.9910
glutamine
Glutamine: A non-essential amino acid present abundantly throughout the body and is involved in many metabolic processes. It is synthesized from GLUTAMIC ACID and AMMONIA. It is the principal carrier of NITROGEN in the body and is an important energy source for many cells.. L-glutamine : An optically active form of glutamine having L-configuration.. glutamine : An alpha-amino acid that consists of butyric acid bearing an amino substituent at position 2 and a carbamoyl substituent at position 4.		2.0110amino acid zwitterion;
glutamine family amino acid;
glutamine;
L-alpha-amino acid;
polar amino acid zwitterion;
proteinogenic amino acid		EC 1.14.13.39 (nitric oxide synthase) inhibitor;
Escherichia coli metabolite;
human metabolite;
metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
Saccharomyces cerevisiae metabolite
xanthenes
Xanthenes: Compounds with three aromatic rings in linear arrangement with an OXYGEN in the center ring.		210xanthene
4-n-bis(2-chloroethyl)aminobenzoic acid
4-N-bis(2-chloroethyl)aminobenzoic acid: structure given in first source		2.3920
phenacid
phenacid: RN given refers to parent cpd; structure		1.9910
hydroxyaniline mustard
hydroxyaniline mustard: structure; RN given refers to parent cpd		1.9910
phenylenediamine mustard
phenylenediamine mustard: RN given refers to parent cpd		1.9910
tretazicar
tretazicar: minor descriptor (75-84); on-line & Index Medicus search AZIRIDINES (75-84)		2.0210
antibiotic g 418
antibiotic G 418: from Micromonospora rhodorangea		1.9910
vadimezan
vadimezan : A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens is replaced by a 5,6-dimethyl-9-oxoxanthen-4-yl group.		210monocarboxylic acid;
xanthones		antineoplastic agent
methotrexate
[no description available]		1.9910dicarboxylic acid;
monocarboxylic acid amide;
pteridines		abortifacient;
antimetabolite;
antineoplastic agent;
antirheumatic drug;
dermatologic drug;
DNA synthesis inhibitor;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
immunosuppressive agent
4-((2-chloroethyl) (2-mesyloxyethyl)amino)benzoic acid
4-((2-chloroethyl) (2-mesyloxyethyl)amino)benzoic acid: structure given in first source		2.6930
4-n-bis(2-chloroethyl)aminobenzoylglutamic acid
4-N-bis(2-chloroethyl)aminobenzoylglutamic acid: structure given in first source		2.3920
ConditionIndicatedRelationship StrengthStudiesTrials
Colorectal Cancer
[description not available]		05.0452
Colorectal Neoplasms
Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.		05.0452
Breast Cancer
[description not available]		02.730
Breast Neoplasms
Tumors or cancer of the human BREAST.		02.730
Bancroftian Elephantiasis
[description not available]		03.9911
Infections, Nematomorpha
[description not available]		04.6831
Elephantiasis, Filarial
Parasitic infestation of the human lymphatic system by WUCHERERIA BANCROFTI or BRUGIA MALAYI. It is also called lymphatic filariasis.		03.9911
Helminthiasis
Infestation with parasitic worms of the helminth class.		04.6831
Adenocarcinoma, Basal Cell
[description not available]		02.4120
Angiogenesis, Pathologic
[description not available]		02.4120
Cancer of Ovary
[description not available]		02.9240
Adenocarcinoma
A malignant epithelial tumor with a glandular organization.		02.4120
Ovarian Neoplasms
Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.		02.9240
Cancer of Colon
[description not available]		02.3920
Colonic Neoplasms
Tumors or cancer of the COLON.		02.3920
Body Weight
The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.		0210
Thrombopenia
[description not available]		03.3911
Neutropenia
A decrease in the number of NEUTROPHILS found in the blood.		03.3911
Thrombocytopenia
A subnormal level of BLOOD PLATELETS.		03.3911